These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 34614542

  • 1. Time Above All Else: Pharmacodynamic Analysis of β-Lactams in Critically Ill Patients.
    Landmesser KB, Clark JA, Burgess DS.
    J Clin Pharmacol; 2022 Apr; 62(4):479-485. PubMed ID: 34614542
    [Abstract] [Full Text] [Related]

  • 2. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
    Shea KM, Cheatham SC, Smith DW, Wack MF, Sowinski KM, Kays MB.
    Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
    [Abstract] [Full Text] [Related]

  • 3. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.
    Koomanachai P, Bulik CC, Kuti JL, Nicolau DP.
    Clin Ther; 2010 Apr; 32(4):766-79. PubMed ID: 20435246
    [Abstract] [Full Text] [Related]

  • 4. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS, Frei CR.
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [Abstract] [Full Text] [Related]

  • 5. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004.
    DeRyke CA, Kuti JL, Nicolau DP.
    Pharmacotherapy; 2007 Mar; 27(3):333-42. PubMed ID: 17316145
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic/pharmacodynamic target attainment of intravenous β-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital.
    Furtado GH, Cardinal L, Macedo RS, Silva JO, Medeiros EA, Kuti JL, Nicolau DP.
    Rev Soc Bras Med Trop; 2015 Mar; 48(5):539-45. PubMed ID: 26516962
    [Abstract] [Full Text] [Related]

  • 7. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation.
    Eagye KJ, Kuti JL, Dowzicky M, Nicolau DP.
    Clin Ther; 2007 May; 29(5):889-899. PubMed ID: 17697907
    [Abstract] [Full Text] [Related]

  • 8. A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004.
    Eagye KJ, Nicolau DP, Lockhart SR, Quinn JP, Doern GV, Gallagher G, Abramson MA.
    Ann Clin Microbiol Antimicrob; 2007 Oct 01; 6():11. PubMed ID: 17908321
    [Abstract] [Full Text] [Related]

  • 9. Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients.
    Heil EL, Nicolau DP, Farkas A, Roberts JA, Thom KA.
    Antimicrob Agents Chemother; 2018 Sep 01; 62(9):. PubMed ID: 29967022
    [Abstract] [Full Text] [Related]

  • 10. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance.
    Crandon JL, Kuti JL, Jones RN, Nicolau DP.
    Ann Pharmacother; 2009 Feb 01; 43(2):220-7. PubMed ID: 19193582
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A Monte Carlo Simulation Approach for Beta-Lactam Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Jang SM, Gharibian KN, Lewis SJ, Fissell WH, Tolwani AJ, Mueller BA.
    J Clin Pharmacol; 2018 Oct 01; 58(10):1254-1265. PubMed ID: 29746711
    [Abstract] [Full Text] [Related]

  • 14. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
    Sun HK, Kuti JL, Nicolau DP.
    Crit Care Med; 2005 Oct 01; 33(10):2222-7. PubMed ID: 16215374
    [Abstract] [Full Text] [Related]

  • 15. Optimal antipseudomonal ꞵ-lactam drug dosing recommendations in critically-ill Asian patients receiving CRRT.
    Jang SM, Lewis SJ, Rhie SJ.
    J Crit Care; 2022 Dec 01; 72():154172. PubMed ID: 36270240
    [Abstract] [Full Text] [Related]

  • 16. Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profiling.
    Eagye KJ, Kuti JL, Nicolau DP.
    Surg Infect (Larchmt); 2007 Apr 01; 8(2):215-26. PubMed ID: 17437367
    [Abstract] [Full Text] [Related]

  • 17. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
    Xiao YH, Hu YJ.
    Zhonghua Nei Ke Za Zhi; 2017 Aug 01; 56(8):595-600. PubMed ID: 28789493
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.